tiprankstipranks
Trending News
More News >
OrganoClick AB (SE:ORGC)
:ORGC
Advertisement

OrganoClick AB (ORGC) AI Stock Analysis

Compare
0 Followers

Top Page

SE

OrganoClick AB

(Frankfurt:ORGC)

Rating:45Neutral
Price Target:
kr1.50
▼(-16.20%Downside)
OrganoClick AB's overall stock score is primarily impacted by its financial performance, which reveals significant challenges with profitability, leverage, and cash flow. Technical analysis further supports a bearish outlook, with all major moving averages indicating a downtrend. Valuation metrics show additional concerns, highlighted by a negative P/E ratio and no dividend yield.

OrganoClick AB (ORGC) vs. iShares MSCI Sweden ETF (EWD)

OrganoClick AB Business Overview & Revenue Model

Company DescriptionOrganoClick AB is a Swedish company specializing in the development and production of environmentally friendly chemical products and technologies. The company's core focus is on creating sustainable alternatives for traditional chemical solutions in sectors such as textiles, construction, and paper. OrganoClick's innovative technologies include biobased binders, water-repellent and flame-retardant coatings, and biodegradable polymers, all aiming to reduce environmental impact while maintaining high performance standards.
How the Company Makes MoneyOrganoClick AB generates revenue through the sale of its proprietary environmentally friendly products and licensing of its technologies. The company's key revenue streams include the sale of biobased binders for nonwoven materials, water-repellent and flame-retardant treatments for textiles, and biodegradable binders for paper and packaging industries. Additionally, OrganoClick collaborates with various industry partners to integrate its sustainable solutions into their products, further expanding its market reach and revenue potential. Strategic partnerships and continuous innovation in green chemistry are significant factors contributing to the company's earnings growth.

OrganoClick AB Financial Statement Overview

Summary
OrganoClick AB faces significant financial challenges across income, balance sheet, and cash flow metrics. The company struggles with profitability, high leverage, and cash flow management, which pose risks to its financial health. While gross profit margin is decent, the persistent net losses and negative cash flow growth highlight critical areas needing improvement.
Income Statement
45
Neutral
OrganoClick AB's income statement shows declining revenue and persistent losses. The TTM (Trailing-Twelve-Months) reveals a gross profit margin of approximately 23.8%, but the net profit margin is negative, indicating struggles with profitability. Revenue growth is inconsistent, and EBIT and EBITDA margins are negative, highlighting operational inefficiencies.
Balance Sheet
50
Neutral
The balance sheet indicates a high debt-to-equity ratio, suggesting significant leverage. The equity ratio stands at about 14.6% TTM, reflecting low equity relative to assets. Persistent net losses have impacted return on equity negatively. The company's financial stability is a concern due to high liabilities and diminishing equity.
Cash Flow
40
Negative
Cash flow analysis reveals negative free cash flow TTM, highlighting cash generation challenges. The operating cash flow to net income ratio is negative, indicating core operational cash flow issues. The growth of free cash flow is negative, pointing to cash management difficulties.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue124.45M127.23M145.87M115.05M110.06M96.46M
Gross Profit29.60M31.84M35.39M12.94M18.51M20.20M
EBITDA3.48M5.71M5.95M-21.19M-12.92M-4.41M
Net Income-19.37M-17.97M-15.77M-41.62M-31.03M-19.52M
Balance Sheet
Total Assets177.04M126.98M150.75M162.86M188.39M152.80M
Cash, Cash Equivalents and Short-Term Investments401.00K538.00K10.74M15.20M34.25M32.03M
Total Debt75.50M50.56M62.39M60.68M53.54M43.36M
Total Liabilities142.93M89.15M97.34M95.30M80.66M69.86M
Stockholders Equity25.78M28.98M44.58M58.78M100.33M54.08M
Cash Flow
Free Cash Flow-7.75M-5.51M-8.08M-35.35M-52.34M-13.93M
Operating Cash Flow3.52M3.60M533.00K-21.22M-37.69M5.47M
Investing Cash Flow-11.28M-9.11M-8.61M-7.45M-14.65M-19.40M
Financing Cash Flow-5.35M-4.69M3.60M9.63M54.56M-15.19M

OrganoClick AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.79
Price Trends
50DMA
2.02
Negative
100DMA
2.16
Negative
200DMA
2.48
Negative
Market Momentum
MACD
-0.05
Positive
RSI
37.75
Neutral
STOCH
34.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Negative. The current price of 1.79 is below the 20-day moving average (MA) of 1.94, below the 50-day MA of 2.02, and below the 200-day MA of 2.48, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 37.75 is Neutral, neither overbought nor oversold. The STOCH value of 34.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ORGC.

OrganoClick AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
€436.50M28.16-4.31%1.17%35.99%95.51%
58
Neutral
kr29.22B-4.46-5.02%3.08%5.87%-67.02%
49
Neutral
kr304.24M-7.20%-3.42%-31.37%
47
Neutral
kr149.03M-42.76%-10.46%-680.00%
45
Neutral
kr175.63M-74.60%-16.35%-33.93%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ORGC
OrganoClick AB
1.70
-1.86
-52.25%
SE:NEXAM
Nexam Chemical Holding AB
3.64
-1.48
-28.91%
SE:POLYG
Polygiene AB
11.70
1.83
18.54%
SE:SERT
Serstech AB
0.61
-1.04
-63.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025